Back in January, Bristol-Myers Squibb ( BMY) paid$ 26 A share to buy biotech company inhibitex, which was an enormous 163% more than where that stock had been trading, and still ranks as the richest deal of the year. 今年1月,百时美施贵宝(Bristol-MyersSquibb)以每股26美元的价格收购了生物科技公司Inhibitex,溢价高达163%,成为今年以来溢价最高的并购交易。
Studies by Bristol-Myers and Merck as well as Roche, which is also developing such a drug, have shown that there was a much greater success rate using the drugs to treat tumors that were positive for PD-L1. 百时美施贵宝、默克与罗氏(Roche)等研发此类药物的公司的研究显示,此类药物在治疗PD-L1呈阳性的肿瘤时有着大得多的成功率。
Bristol-Myers Squibb Co. is conducting several early stage studies on CGRP antagonists and other companies are testing or may begin development of similar compounds as well. 百时美施贵宝公司(Bristol-MyersSquibbCo.)正在进行几种CGRP拮抗药的早期研究,其它公司也在对类似药物进行测试或者准备开始进行开发。
Shares on Bristol-Myers have held up relatively well over the course of the past year. 勃列斯多•迈耶的股票在过去的一年当中表现相对较好。
Demanding evidence that a drug prolongs life may make it harder to gain FDA support for Pfizer and Bristol-Myers, analysts say. 分析员说:对药物延长寿命的要求必然使辉瑞和百时美施贵宝的计划实现难度加大。
Role and Practice of Bioanalysis in Drug Discovery and Development, Mingshe Zhu, Ph.D., Bristol-Myers Squibb, NJ, USA. 生物分析在药物研发中的功能和实践,朱明社博士,部门主管,百时美-施贵宝药业(美国)
Fortunately, Bristol-Myers has a diverse portfolio that is not under immediate pressure from expiring patent protection. 幸运的是,勃列斯多•迈耶拥有不同类型的投资组合,这使得在即将到期的专利保护下没有直接的压力。
The Bristol-Myers compound works differently than the protease inhibitors being developed by Merck's Schering-Plough division and Vertex Pharmaceuticals Inc. 百时美施贵宝公司的这种化合作用机制与以前由先灵葆雅公司推出的和顶点医药公司的蛋白酶抑制剂不同。
If it does go ahead with layoffs, Wyeth will have plenty of company. Amgen, J& J, Bristol-Myers, AstraZeneca and Novartis have all announced job cuts in recent months. 如果裁员继续,惠氏将有很多同伴。安进公司、强生公司、施贵宝、阿斯利康和诺华公司都已宣布在最近几个月内将进行裁员。
Thus, speculation has become a takeover target Pfizer today's hottest topic: Bristol-Myers Squibb? 于是,猜测辉瑞的收购目标成了当前最热门的话题:百时美施贵宝?
Optimization in Drug Candidate Selection and Strategy in Early Drug Development, Wen Chyi Shyu, Ph.D., Bristol-Myers Squibb, NJ, USA. 药物在筛选中的优化以及在早期开发中的策略徐文祺博士,高级主管,百时美-施贵宝药业(美国)
Bristol-Myers Squibb Company ( NYSE: BMY) announced the results at the18th Conference of the Asia-Pacific Association for the Study of the Liver in Seoul, Korea. BMY公司在第韩国首尔召开的十八届亚太肝脏研究学会年会上公布了这些结果。
Some common medications include metformin, which is available generically and also known by the Bristol-Myers Squibb brand name Glucophage. 一些常用药包括非专利药二甲双胍,它是百时美施贵宝公司的产品,商品名叫格华止。
Metformin is available generically but also known by the Bristol-Myers Squibb brand name Glucophage. 二甲双胍是一类有效的降糖药,勃列斯多-迈耶施贵宝药厂生产的商品名为格华止。
This combination will make Bristol-Myers a compelling stock to watch as the pharmaceutical industry continues to transform itself. 作为持续保持自身改革的制药行业,这些措施能使勃列斯多•迈耶的股票变强值得关注。